Protection against glutamatergic toxicity is also afforded by orexin, which increases levels of astrocyte GLT-1 [142], highlighting another similarity in the effects of orexin and melatonin on MS pathophysiology. The gene discussed is HCRT; the disease is myeloid sarcoma.